NanoLogix Announces Expansion of EPA Work on Rapid Tests for Drinking Water Quality & Provides Update on Publication of Group...
July 19 2011 - 6:30AM
Business Wire
NanoLogix (OTC MARKETS: NNLX), a biotechnology innovator in the
rapid detection and identification of live-cell bacteria and
microorganisms, announced today the U.S. Environmental Protection
Agency (EPA) intends to expand its Cooperative Research And
Development Agreement (CRADA) with NanoLogix to include additional
water-borne pathogens. To accommodate the additional research, the
company will add two scientists to its staff at its Cincinnati
laboratory. More information on the NanoLogix CRADA can be found at
the EPA MCEARD News Archive where an article on the company's work
can be found two-thirds down the page.
University of Texas Health Science Center - Houston Group B
Streptococcus Update
NanoLogix is pleased to announce Phase I of the Group B Strep
research utilizing NanoLogix technology is expected to be published
by the end of August, 2011 in a major peer-reviewed American
medical journal. In addition, lead researcher on the UTHSC-Houston
clinical trial, Dr. Jonathan Faro M.D., Ph.D., assistant professor
in General Obstetrics & Gynecology at UTHSC-Houston, will
present these Phase I findings at the Central Association of
Obstetricians and Gynecologists Annual Meeting on October 26-29,
2011. Results of the completed UTHSC Phase II trial are currently
being prepared for publication. Meanwhile, the final phase of the
300-patient clinical trial (constituting Phase III of the Group B
Strep trial) is on-going and nearing completion.
NanoLogix In the News
Recently, NanoLogix technology has been featured prominently in
several media outlets, including:
- Pharmaceutical Manufacturing: Rapid Microbiological
Technologies- A Talk With Bret Barnhizer of NanoLogix
- MedCity News: NanoLogix eyes FDA clearance of rapid
diagnostic bacteria tests
- Medical Laboratory Observer: NanoLogix’ Barnhizer
accelerates the rapid detection “revolution”
- Lab Manager Magazine: Bacterial Culturing for Faster
Microbe Detection
About NanoLogix, Inc.
NanoLogix is a biotechnology company focused primarily on rapid
diagnostics. Its products offer accelerated detection and
identification of microorganisms. In addition to medical and
homeland security applications, NanoLogix technology is applicable
in pharmaceutical, industrial, veterinary and environmental
testing. Patents granted to NanoLogix can be used in the areas of
applied microbiology, soil microbiology and bioremediation,
microbial physiology, molecular biology, pharmacology,
pharmaco-kinetics, and antibiotic sensitivity. For more information
visit www.nanologix.com.
This press release contains statements, which may constitute
"forward- looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange Act of 1934, as amended by
the Private Securities Litigation Reform Act of 1995. Those
statements include statements regarding the intent, belief or
current expectations of NanoLogix, Inc., and members of its
management as well as the assumptions on which such statements are
based. Prospective investors are cautioned that any such
forward-looking statements are not guarantees of future performance
and involve risks and uncertainties, and that actual results may
differ materially from those contemplated by such forward-looking
statements. The Company undertakes no obligation to update or
revise forward-looking statements to reflect changed assumptions,
the occurrence of unanticipated events or changes to future
operating results.
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From Apr 2024 to May 2024
NanoLogix (CE) (USOTC:NNLX)
Historical Stock Chart
From May 2023 to May 2024